Balversa (erdafitinib) — CareFirst (Caremark)

Initial criteria

• Diagnosis of bladder cancer with FGFR3 genetic alterations
• Used as a single agent
• Used as subsequent therapy
• Patient has one of the following: Stage II disease with tumor present following reassessment 2–3 months after primary treatment with concurrent bladder-preserving chemoradiotherapy and maximal transurethral resection of bladder tumor (TURBT), OR locally advanced disease, OR metastatic disease, OR local recurrence, OR persistent disease in a preserved bladder

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months